Evidence map›Paper›PMID 35986147›Full record

ArticlePediatric research2023

Propranolol ameliorates retinopathy of prematurity in mice by downregulating HIF-1α via the PI3K/Akt/ERK pathway.

Shaomin Su, Peicen Zou, Guangran Yang, Yajuan Wang, Lei Liu, Ying Liu, Jinjing Zhang, Yijun Ding

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Shaomin Su *Department of Neonatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Peicen Zou *Department of Neonatology, Capital Institute of Pediatrics, Beijing, China.
Guangran YangDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yajuan WangDepartment of Neonatology, Children's Hospital, Capital Institute of Pediatrics, Beijing, China. cxswyj@vip.sina.com.
Lei LiuDepartment of Neonatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Ying LiuDepartment of Neonatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jinjing ZhangDepartment of Neonatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yijun DingDepartment of Neonatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Beijing Children’s Hospital · CNCapital Medical University · CNCapital Institute of Pediatrics · CNChildren's Hospital of Capital Institute of Pediatrics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetinopathy of prematurity (ROP) is the leading cause of blindness in infants, and elevation of HIF-1α through the PI3K/Akt and ERK pathways is implicated in ROP pathogenesis. The mechanism of action of propranolol in ROP remains controversial. We investigated the effect of propranolol on ROP and explored its potential mechanisms of action in an oxygen-induced retinopathy (OIR) mouse model.

methodsOIR mice were first treated with propranolol intraperitoneally, and the retina integrity was measured by FITC-dextran and hematoxylin-eosin staining. The expression of HIF-1α, VEGF, and key signaling pathway proteins was determined using real-time PCR and western blotting.

resultsFITC-dextran staining showed that propranolol treatment reduced damage to retinal morphology in OIR mice. Mice treated with propranolol showed a reduced number of nuclei of vascular endothelial cells penetrating the inner limiting membrane of the retina, confirming the therapeutic effect of propranolol on ROP. Further analysis showed that HIF-1α and PI3K/Akt/ERK pathway protein levels were significantly elevated in OIR mice. In contrast, propranolol treatment downregulated the expression of these proteins, indicating that the PI3K/Akt/ERK/HIF-1α axis is associated with propranolol-induced ROP alleviation.

conclusionsPropranolol has a therapeutic function against ROP, likely through the downregulation of HIF-1α via the PI3K/Akt/ERK pathway. IMPACT: Propranolol can reduce the formation of abnormal retinal neovascularization in oxygen-induced retinopathy (OIR) models, and reduce leaking, tortuous, and abnormally expanding retinal blood vessels. Propranolol possibly improves OIR by inhibiting the activated ERK and HIF-1α pathways. Furthermore, propranolol may downregulate HIF-1α via the PI3K/Akt/ERK pathway to ameliorate retinopathy of prematurity. This study elucidated that the therapeutic effect of propranolol in OIR mice does not involve the VEGFR-2 pathway.

Indexed as

Retinal NeovascularizationRetinopathy of PrematurityAnimalsDextransDisease Models, AnimalEndothelial CellsFluorescein-5-isothiocyanateHumansInfant, NewbornMAP Kinase Signaling SystemMiceMice, Inbred C57BLOxygenPhosphatidylinositol 3-KinasesPropranololProto-Oncogene Proteins c-aktDextransFluorescein-5-isothiocyanatefluorescein isothiocyanate dextranOxygenPhosphatidylinositol 3-KinasesPropranololProto-Oncogene Proteins c-akt

Identifiers

PMID35986147
OpenAlexW4292296651

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.